menu
    • menu
    [{"orgOrder":0,"company":"Domainex","sponsor":"LUNAC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Protease","graph1":"Hematology","graph2":"Discovery","graph3":"Domainex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Domainex \/ LUNAC Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/ LUNAC Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"PBGENE-HbE","moa":"","graph1":"Hematology","graph2":"Discovery","graph3":"Precision BioSciences","amount2":1.48,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":1.48,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Reachbio Research Labs","sponsor":"Discovery Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Discovery","graph3":"Reachbio Research Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Reachbio Research Labs \/ Discovery Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Reachbio Research Labs \/ Discovery Life Sciences"},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Discovery","graph3":"Orna Therapeutics","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Orna Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Orna Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":1.24,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Scribe Therapeutics \/ Sanofi"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Scribe Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Scribe Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Discovery

                            Sponsor : Sanofi

                            Deal Size : $1,240.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Scribe Therapeutics Achieves Milestone for in Vivo Program in Collaboration with Sanofi

                            Details : Under the collaboration, Sanofi has exercised its option for a second target as part of the companies' research collaboration to develop CRISPR-based therapeutics using Scribe’s CRISPR technologies.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $40.0 million

                            January 13, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Discovery

                            Sponsor : Sanofi

                            Deal Size : $1,240.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orna Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Orna Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Discovery

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $700.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orna, Vertex Partner on SCD, Beta Thalassemia Gene Therapy Development

                            Details : Through the collaboration, Vertex will utilize Orna's proprietary LNP delivery solutions to enhance it's efforts in developing next-gen gene editing therapies for patients with SCD and TDT.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $65.0 million

                            January 07, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Discovery

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $700.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Reachbio Research Labs

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Reachbio Research Labs

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Discovery

                            Sponsor : Discovery Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Discovery Life Sciences Acquires ReachBio Research Labs

                            Details : The Acquisition aims to enhance cell biology capabilities and accelerate assessments of potential new drug targets in hematologic diseases, cell and gene therapy, immunology, oncology, and immuno-oncology.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 11, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Discovery

                            Sponsor : Discovery Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Precision BioSciences

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Precision BioSciences

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PBGENE-HbE

                            Therapeutic Area : Hematology

                            Study Phase : Discovery

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,475.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curati...

                            Details : Under the terms of the Agreement, Precision will develop an ARCUS nuclease and conduct in vitro characterization, with Novartis then assuming responsibility for all subsequent research, development, manufacturing and commercialization activities of PBGEN...

                            Product Name : PBGENE-HbE

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $75.0 million

                            June 21, 2022

                            Lead Product(s) : PBGENE-HbE

                            Therapeutic Area : Hematology

                            Highest Development Status : Discovery

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,475.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Domainex

                            United Kingdom arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Domainex

                            United Kingdom arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Discovery

                            Sponsor : LUNAC Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Domainex inks partnership with LUNAC Therapeutics to discover novel anticoagulant therapies

                            Details : The partnership aims at discovering a drug that inhibits the protease target, activated Factor XII.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 25, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Discovery

                            Sponsor : LUNAC Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth